Severe psychiatric disturbance and attempted suicide in a patient with COVID-19 and no psychiatric history

Gillett, George; Jordan, Iain

doi:10.1136/bcr-2020-239191

Cited by 34 publications

(31 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…( 10 ) Although anti-neural autoantibodies are present in some neurologically impaired COVID-19 patients(11-13), autoantibody studies are rarely performed in cases of COVID-19-associated psychosis. ( 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 )…”

Section: Discussionmentioning

confidence: 99%

RETRACTED: Remission of Subacute Psychosis in a COVID-19 Patient With an Antineuronal Autoantibody After Treatment With Intravenous Immunoglobulin

McAlpine

Lifland

Check

et al. 2021

Biological Psychiatry

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

RETRACTED: Remission of Subacute Psychosis in a COVID-19 Patient With an Antineuronal Autoantibody After Treatment With Intravenous Immunoglobulin

McAlpine

Lifland

Check

et al. 2021

Biological Psychiatry

View full text Add to dashboard Cite

“…These findings correspond to those reported by Wang et al, 23 who found higher rates of COVID-19 hospitalizations among patients with severe mental illnesses in the United States. It has been previously offered that biological factors related to neuroinflammation may contribute to the association between psychiatric disturbances and COVID-19, 26 mainly in patients with a new onset of psychiatric symptoms. An additional explanation to account for the higher rates of hospitalization is related to medical, behavioral, and environmental risk factors.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 Prevalence and Mortality Among Schizophrenia Patients: A Large-Scale Retrospective Cohort Study

Bitan

Krieger

Kridin

et al. 2021

Schizophrenia Bulletin

View full text Add to dashboard Cite

Objective Individuals with schizophrenia may be at an increased risk for COVID-19 morbidity due to the disease characteristics. In this study, we aimed to explore the odds of significant COVID-19 morbidity and mortality among schizophrenia patients while controlling for potential sociodemographic and medical confounders. Methods Schizophrenia patients and age-and-sex matched controls (total n = 51 078) were assessed for frequency of COVID-19 positivity, hospitalizations, and mortality. The odds for COVID-19-associated hospitalization and mortality were calculated using logistic regression models, while controlling for age, sex, marital status, sector, socioeconomic status, diabetes, ischemic heart disease, hypertension, hyperlipidemia, obesity, smoking, and chronic obstructive pulmonary disease. Results Individuals with schizophrenia were less likely to test positive for COVID-19; however, they were twice as likely to be hospitalized for COVID-19 (OR 2.15 95% CI 1.63–2.82, P < .0001), even after controlling for sociodemographic and clinical risk factors (OR 1.88 95% CI 1.39–2.55, P < .0001). Furthermore, they were 3 times more likely to experience COVID-19 mortality (OR 3.27 95% CI 1.39–7.68, P < .0001), compared to controls. Conclusions We found evidence of associations between schizophrenia and increased COVID-19 morbidity and mortality compared to controls regardless of sociodemographic and medical factors. As these patients present with a combination of potential risk factors for mortality, efforts should be made to minimize the effects of the pandemic on this vulnerable population.

show abstract

“…In one study, 3.5% of respondents reported suicidality at 1 month following infection [ 33 ]. There have been numerous case reports of COVID-19 patients attempting to kill themselves during or prior to hospitalization [ 13 , 39 , 40 ]. Nonetheless, it remains prudent to withhold final judgment on the relationship between COVID-19 and suicide until definitive epidemiological studies can be completed [ 41 ].…”

Section: Introductionmentioning

confidence: 99%

Neuropsychiatric Complications of COVID-19

Nakamura

Nash

Laughon

et al. 2021

Curr Psychiatry Rep

104

View full text Add to dashboard Cite

Purpose of Review To describe the presentation, etiologies, and suggested management of post-acute COVID-19 neuropsychiatric symptoms. Recent Findings Over 30% of patients hospitalized with COVID-19 may exhibit cognitive impairment, depression, and anxiety that persist for months after discharge. These symptoms are even more common in patients who required intensive care for severe effects of the virus. In addition to the pandemic-related psychological stress, multiple biological mechanisms have been proposed to understand the neuropsychiatric symptoms observed with COVID-19. Given limited research regarding effective interventions, we recommend pharmacologic and behavioral strategies with established evidence in other medically-ill populations. Summary Long-term, neuropsychiatric complications of COVID-19 are common and consequential. Because these are likely to co-occur with other medical problems, patients recovering from COVID-19 are best managed in clinics with highly coordinated care across disciplines and medical specialties. Future research is needed to inform appropriate interventions.

show abstract

Severe psychiatric disturbance and attempted suicide in a patient with COVID-19 and no psychiatric history

Cited by 34 publications

References 27 publications

RETRACTED: Remission of Subacute Psychosis in a COVID-19 Patient With an Antineuronal Autoantibody After Treatment With Intravenous Immunoglobulin

RETRACTED: Remission of Subacute Psychosis in a COVID-19 Patient With an Antineuronal Autoantibody After Treatment With Intravenous Immunoglobulin

COVID-19 Prevalence and Mortality Among Schizophrenia Patients: A Large-Scale Retrospective Cohort Study

Neuropsychiatric Complications of COVID-19

Contact Info

Product

Resources

About